Enhanced Delivery\nand Potency of Chemotherapeutics\nin Melanoma Treatment via Magnetite Nanobioconjugates

Melanoma, known for\nits aggressive metastatic potential,\nposes\nsignificant treatment challenges. Despite the potent antiproliferative\neffects of anticancer drugs, systemic toxicity and low water solubility\nlimit their efficacy. This study addresses these challenges by employing\nmagnetite (Fe<sub>3</sub>O<sub>4</sub>) nanobioconjugates as a drug\ndelivery system, aimed at enhancing drug solubility and reducing off-target\neffects in melanoma therapy. Magnetite nanoparticles (MNPs) were engineered\nwith functional molecules and loaded with the anticancer agents Temozolomide\n(TMZ) or paclitaxel (PTX). The nanobioconjugates were characterized\nvia Fourier transform infrared spectroscopy (FTIR), thermogravimetric\nanalysis (TGA), dynamic light scattering (DLS), and transmission electron\nmicroscopy (TEM). The results validated the efficacious synthesis\nand drug loading, attaining efficiencies ranging from 32 to 72% for\nTMZ and 32 to 60% for PTX. Biocompatibility assessments demonstrated\nexcellent tolerance, with minimal hemolysis rates and platelet aggregation.\nIn vitro studies revealed enhanced cytotoxicity against A-375 human\nmelanoma cells compared to free drugs, with cellular uptake facilitated\nprimarily through macropinocytosis, caveolin-, and clathrin-mediated\nendocytosis. Furthermore, the nanobioconjugates exhibited significant\nefficacy in targeting A-375 melanoma spheroids, underlining their\npotential in melanoma therapy. This research underscores magnetite\nnanobioconjugates as a promising avenue for targeted melanoma treatment,\noffering enhanced drug delivery specificity and reduced systemic toxicity\nin oncological drug delivery systems.